Donanemab has already received a 'breakthrough therapy' designation from the FDA
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial
8-mg dose of naloxone hydrochloride nasal spray now approved with 2-mg and 4-mg doses